United Therapeutics (NASDAQ:UTHR) CEO Martine Rothblatt Sells 9,500 Shares

United Therapeutics Corporation (NASDAQ:UTHR) CEO Martine Rothblatt sold 9,500 shares of the company’s stock in a transaction on Friday, June 5th. The shares were sold at an average price of $547.62, for a total value of $5,202,390.00. Following the completion of the transaction, the chief executive officer directly owned 40,513 shares in the company, valued at approximately $22,185,729.06. The trade was a 19.00% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

United Therapeutics Stock Performance

Shares of NASDAQ UTHR traded down $5.18 during mid-day trading on Monday, hitting $544.69. The stock had a trading volume of 431,236 shares, compared to its average volume of 480,455. The company has a 50 day moving average of $568.23 and a two-hundred day moving average of $519.16. United Therapeutics Corporation has a twelve month low of $272.12 and a twelve month high of $609.35. The firm has a market cap of $23.12 billion, a PE ratio of 20.11, a PEG ratio of 1.79 and a beta of 0.57.

United Therapeutics (NASDAQ:UTHR) last released its earnings results on Wednesday, May 6th. The biotechnology company reported $5.82 earnings per share (EPS) for the quarter, missing the consensus estimate of $7.00 by ($1.18). United Therapeutics had a net margin of 40.62% and a return on equity of 19.24%. The firm had revenue of $781.50 million during the quarter, compared to analyst estimates of $797.40 million. During the same period in the previous year, the company earned $6.63 earnings per share. United Therapeutics’s revenue was down 1.6% on a year-over-year basis. Equities research analysts predict that United Therapeutics Corporation will post 26.84 EPS for the current fiscal year.

Analyst Ratings Changes

Several equities research analysts have weighed in on UTHR shares. Bank of America increased their price target on United Therapeutics from $569.00 to $626.00 and gave the stock a “neutral” rating in a research report on Tuesday, March 31st. Raymond James Financial assumed coverage on United Therapeutics in a research report on Friday, April 10th. They set an “outperform” rating and a $700.00 price target on the stock. Wells Fargo & Company upgraded United Therapeutics from an “equal weight” rating to an “overweight” rating and raised their target price for the company from $575.00 to $735.00 in a research report on Thursday, May 7th. Morgan Stanley set a $516.00 target price on United Therapeutics in a research report on Thursday, May 7th. Finally, Cantor Fitzgerald raised their target price on United Therapeutics from $525.00 to $625.00 and gave the company an “overweight” rating in a research report on Thursday, March 12th. Eleven research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $619.42.

Institutional Investors Weigh In On United Therapeutics

A number of institutional investors have recently modified their holdings of the business. Torren Management LLC purchased a new position in United Therapeutics in the 4th quarter valued at about $26,000. Activest Wealth Management lifted its stake in United Therapeutics by 1,400.0% in the 4th quarter. Activest Wealth Management now owns 60 shares of the biotechnology company’s stock valued at $29,000 after buying an additional 56 shares in the last quarter. Entrust Financial LLC purchased a new position in United Therapeutics in the 4th quarter valued at about $31,000. International Assets Investment Management LLC lifted its stake in United Therapeutics by 426.7% in the 1st quarter. International Assets Investment Management LLC now owns 79 shares of the biotechnology company’s stock valued at $45,000 after buying an additional 64 shares in the last quarter. Finally, Wilmington Savings Fund Society FSB lifted its stake in United Therapeutics by 125.6% in the 3rd quarter. Wilmington Savings Fund Society FSB now owns 88 shares of the biotechnology company’s stock valued at $37,000 after buying an additional 49 shares in the last quarter. 94.08% of the stock is currently owned by institutional investors and hedge funds.

About United Therapeutics

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.